Champions Oncology (CSBR) Change in Receivables (2013 - 2026)
Champions Oncology (CSBR) recorded quarterly Change in Receivables of $498000.0 in Q1 2026, down 76.03% quarter-over-quarter from $2.1 million in Q4 2025, and down 90.55% on a YoY basis from $5.3 million in Q1 2025.
Champions Oncology (CSBR) Change in Receivables (2013 - 2026) Analysis & Trends
Champions Oncology's Change in Receivables history runs 14 years deep, the most recent figure standing at $498000.0 for Q1 2026.
- In Q1 2026, Change in Receivables fell 90.55% year-over-year to $498000.0; the TTM figure through Jan 2026 stood at -$3.7 million (down 147.65% YoY), while the FY2025 annual figure was $1.4 million, down 27.88% from the prior year.
- Change in Receivables was $498000.0 for Q1 2026 at Champions Oncology, down from $2.1 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $5.3 million in Q1 2025 to a low of -$4.5 million in Q2 2025.
- Historically, Change in Receivables has averaged $260764.7 across 5 years, with a median of $250000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables sank 353.49% in 2023, then jumped 2500.0% in 2024.
- A 5-year view of Change in Receivables shows it stood at -$276000.0 in 2022, then plunged by 317.39% to -$1.2 million in 2023, then surged by 206.68% to $1.2 million in 2024, then surged by 69.08% to $2.1 million in 2025, then slumped by 76.03% to $498000.0 in 2026.
- The last three Change in Receivables figures came in at $498000.0 (Q1 2026), $2.1 million (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -4.08 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 498,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 498,000.00 |
| Jan 31, 2026 | 498,000.00 |
| Oct 31, 2025 | 2.08 Mn |
| Oct 31, 2025 | 2.08 Mn |
| Jul 31, 2025 | -1.76 Mn |
| Jul 31, 2025 | -1.76 Mn |
| Apr 30, 2025 | -4.50 Mn |
| Apr 30, 2025 | -4.50 Mn |
| Jan 31, 2025 | 5.27 Mn |
| Jan 31, 2025 | 5.27 Mn |
| Oct 31, 2024 | 1.23 Mn |
| Oct 31, 2024 | 1.23 Mn |
| Jul 31, 2024 | -565,000.00 |
| Jul 31, 2024 | -565,000.00 |
| Apr 30, 2024 | 1.79 Mn |
| Apr 30, 2024 | 1.79 Mn |
| Jan 31, 2024 | 250,000.00 |
| Jan 31, 2024 | 250,000.00 |
| Oct 31, 2023 | -1.15 Mn |
| Oct 31, 2023 | -1.15 Mn |